注射用维贝柯妥塔单抗（美佑恒）老百姓大药房到货

动脉网11-19

近日，国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗（美佑恒）上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者，为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物，由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成，通过抑制微管生成、阻断有丝分裂并诱导凋亡，还具ADCC作用，体外可杀伤多种EGFR表达水平的肿瘤细胞，抑制...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584973709?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-19 18:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2584973709","market":"hk","top_or_hot":-1,"title":"注射用维贝柯妥塔单抗（美佑恒）老百姓大药房到货","media":"动脉网","content":"<div>\n<p>近日，国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗（美佑恒）上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者，为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物，由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成，通过抑制微管生成、阻断有丝分裂并诱导凋亡，还具ADCC作用，体外可杀伤多种EGFR表达水平的肿瘤细胞，抑制...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119182415950e39c6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>注射用维贝柯妥塔单抗（美佑恒）老百姓大药房到货</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n注射用维贝柯妥塔单抗（美佑恒）老百姓大药房到货\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-19 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119182415950e39c6&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗（美佑恒）上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者，为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物，由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成，通过抑制微管生成、阻断有丝分裂并诱导凋亡，还具ADCC作用，体外可杀伤多种EGFR表达水平的肿瘤细胞，抑制...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119182415950e39c6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119182415950e39c6&s=b","article_id":"2584973709","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119182415950e39c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584973709","pubTimestamp":1763546580,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗（美佑恒）上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者，为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物，由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成，通过抑制微管生成、阻断有丝分裂并诱导凋亡，还具ADCC作用，体外可杀伤多种EGFR表达水平的肿瘤细胞，抑制不同EGFR表达水平的细胞来源异种移植模型及奥希替尼耐药肺癌人源性肿瘤组织异种移植模型的肿瘤生长。该药品为处方药，需凭合格处方购买，遵医嘱使用。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物-B"},"translate_title":"Vibecotutamab for injection (Meiyouheng) arrived at the People's Pharmacy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"近日，国家药监局附条件批准乐普生物的注射用维贝柯妥塔单抗（美佑恒）上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌成人患者，为患者提供新治疗选择。该药是靶向EGFR的抗体偶联药物，由人源化IgG1单抗与微管蛋白抑制剂MMAE经可裂解连接子偶联而成，通过抑制微管生成、阻断有丝分裂并诱导凋亡，还具ADCC作用，体外可杀伤多种EGFR表达水平的肿瘤细胞，抑制不同EGFR表达水平的细胞来源异种移植模型及奥希替尼耐药肺癌人源性肿瘤组织异种移植模型的肿瘤生长。该药品为处方药，需凭合格处方购买，遵医嘱使用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584973709","isCrawlerRequest":true}